Bringing Enhanced Cancer Care to Singapore with Varian's Halcyon System

PALO ALTO, Calif., and SINGAPORE, Sept. 7, 2020 /PRNewswire/ -- Varian (NYSE: VAR) today announced that Proton Therapy Pte. Ltd. has placed an order for a Halcyon system, making them the first to bring this innovative treatment platform into Singapore, with the aim of treating the first patient by the end of the year.

Dr. Djeng Shih Kien, chairman, Proton Therapy Pte. Ltd. said: "We are proud to be at the forefront of bringing new technology into Singapore. Radiation therapy has a huge role to play in fighting the ever-growing number of cancer cases in this country and region. By harnessing the technology of Halcyon, we will be able to automate, streamline, and simplify virtually every aspect of treatment. This means we can offer more precise, efficient treatments when compared to conventional machines, while being able to improve patients' comfort by operating in a patient-centric environment."

The Halcyon radiotherapy system can enhance image-guided volumetric intensity-modulated radiotherapy (IMRT). With its streamlined workflow, Halcyon only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies, a simplicity that also take less in total treatment time. Halcyon is an advanced system that is more comfortable for the patient while delivering ease of use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training, and automated treatment.

Kevin Lo, managing director, Southeast Asia, Korea, Hong Kong & Macau Region, Varian Asia Pacific said: "We are delighted to continue our strong partnership with Proton Therapy Pte. Ltd. In addition to the Halcyon system, we are currently installing a Varian ProBeam Compact system at their site in Singapore's international biomedical hub, Biopolis. We believe that, by providing the newest capabilities to healthcare providers, we can help make cancer a chronically managed disease. With both technologies in place, we are well on our way to seeing our vision of living in a world without fear of cancer, become a reality."

The Halcyon system is suited to handle the majority of cancer patients, offering advanced treatments for some of Singapore's most common cancers, including prostate and breast cancer.¹

Proton Therapy Pte. Ltd. is a fully owned subsidiary of Singapore Institute of Advanced Medicine Holdings Pte. Ltd.

About Varian
At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 10,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

¹ Singapore Cancer Society: https://www.singaporecancersociety.org.sg/learn-about-cancer/cancer-basics/common-types-of-cancer-in-singapore.html Accessed 19 July 2020

Press Contact
Christine Hogseth-Gill
Head of Public Affairs, Asia Pacific and Japan
+65 93881352 
christine.hogseth-gill@varian.com

Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com

SOURCE Varian Medical Systems